Axsome Therapeutics Stock Forecast, Price & News

-0.95 (-1.77 %)
(As of 04/15/2021 12:00 AM ET)
Today's Range
Now: $52.60
50-Day Range
MA: $61.70
52-Week Range
Now: $52.60
Volume181,917 shs
Average Volume303,540 shs
Market Capitalization$1.97 billion
P/E RatioN/A
Dividend YieldN/A
Axsome Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05, which is in the phase III clinical trial for the treatment resistant depression and depressive disorders; and phase II/III clinical trials in agitation associated with Alzheimer's disease, as well as completed phase II clinical trial for the treatment of smoking cessation. The company is also developing AXS-07, which is in phase III clinical trial for the treatment of migraine; AXS-09 that has completed phase II clinical trial for the treatment of various CNS disorders; AXS-12, which has completed phase II clinical trial for the treatment of in narcolepsy; and AXS-14, an investigational medicine that is in phase III for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was founded in 2012 and is based in New York, New York.
Axsome Therapeutics logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:AXSM
Year FoundedN/A



Sales & Book Value

Annual SalesN/A
Book Value$5.18 per share


Net Income$-68,350,000.00


Market Cap$1.97 billion
Next Earnings Date5/14/2021 (Estimated)


Oversold Conditions For Axsome Therapeutics
March 30, 2021 |
Axsome Therapeutics (NASDAQ:AXSM) Shares Gap Down to $63.53
March 24, 2021 |
1 Green Flag for Axsome Therapeutics
March 11, 2021 |
Forget Bitcoin: This Biotech Stock Is a Better Buy in 2021
February 10, 2021 |
AXSM Feb 2021 55.000 put
January 30, 2021 |
AXSM Feb 2021 80.000 call
January 30, 2021 |
AXSM Feb 2021 87.500 put
January 29, 2021 |
AXSM Feb 2021 77.500 call
January 29, 2021 |
Is It Too Late to Get In On This Millionaire-Making Stock?
January 27, 2021 |
See More Headlines


Overall MarketRank

1.39 out of 5 stars

Medical Sector

665th out of 2,021 stocks

Pharmaceutical Preparations Industry

321st out of 772 stocks

Analyst Opinion: 3.4Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
-0.95 (-1.77 %)
(As of 04/15/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AXSM News and Ratings via Email

Sign-up to receive the latest news and ratings for AXSM and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Axsome Therapeutics (NASDAQ:AXSM) Frequently Asked Questions

Is Axsome Therapeutics a buy right now?

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Axsome Therapeutics in the last twelve months. There are currently 1 sell rating and 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Axsome Therapeutics stock.
View analyst ratings for Axsome Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Axsome Therapeutics?

Wall Street analysts have given Axsome Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Axsome Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Axsome Therapeutics' next earnings date?

Axsome Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, May 14th 2021.
View our earnings forecast for Axsome Therapeutics

How were Axsome Therapeutics' earnings last quarter?

Axsome Therapeutics, Inc. (NASDAQ:AXSM) released its quarterly earnings data on Sunday, February, 28th. The company reported ($0.78) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.73) by $0.05.
View Axsome Therapeutics' earnings history

How has Axsome Therapeutics' stock been impacted by Coronavirus?

Axsome Therapeutics' stock was trading at $73.65 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, AXSM shares have decreased by 28.6% and is now trading at $52.60.
View which stocks have been most impacted by COVID-19

What price target have analysts set for AXSM?

11 brokers have issued twelve-month price targets for Axsome Therapeutics' shares. Their forecasts range from $66.00 to $210.00. On average, they expect Axsome Therapeutics' stock price to reach $152.67 in the next year. This suggests a possible upside of 190.2% from the stock's current price.
View analysts' price targets for Axsome Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Axsome Therapeutics' key executives?

Axsome Therapeutics' management team includes the following people:
  • Dr. Herriot Tabuteau M.D., Founder, Chairman, CEO & Pres (Age 53, Pay $761.25k)
  • Mr. Nick Pizzie CPA, M.B.A., Chief Financial Officer (Age 46, Pay $520k)
  • Mr. Mark L. Jacobson, COO & Sec. (Age 38)
  • Dr. Cedric O'Gorman M.B.A., M.D., MBA, Sr. VP of Medical Affairs (Age 45)
  • Dr. Amanda Jones Pharm.D., Sr. VP of Clinical Devel. (Age 37)
  • Ms. Lori Englebert, Sr. VP of Commercial & Bus. Devel.
  • Mr. Kevin Laliberte Pharm.D., Exec. VP of Product Strategy (Age 43)
  • Joseph Debrah-Afful CPA, M.B.A., Director of Fin.

Who are some of Axsome Therapeutics' key competitors?

What other stocks do shareholders of Axsome Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Axsome Therapeutics investors own include Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Dicerna Pharmaceuticals (DRNA), Amarin (AMRN), Sarepta Therapeutics (SRPT), Micron Technology (MU), Pfizer (PFE), AbbVie (ABBV), Alibaba Group (BABA) and Bristol-Myers Squibb (BMY).

When did Axsome Therapeutics IPO?

(AXSM) raised $52 million in an initial public offering on Thursday, November 19th 2015. The company issued 4,300,000 shares at $11.00-$13.00 per share. Ladenburg Thalmann and Cantor Fitzgerald & Co. served as the underwriters for the IPO and Brean Capital was co-manager.

What is Axsome Therapeutics' stock symbol?

Axsome Therapeutics trades on the NASDAQ under the ticker symbol "AXSM."

Who are Axsome Therapeutics' major shareholders?

Axsome Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Baldwin Brothers Inc. MA (0.07%) and Private Capital Group LLC (0.00%). Company insiders that own Axsome Therapeutics stock include Mark Coleman, Mark E Saad and Nick Pizzie.
View institutional ownership trends for Axsome Therapeutics

Which major investors are selling Axsome Therapeutics stock?

AXSM stock was sold by a variety of institutional investors in the last quarter, including Baldwin Brothers Inc. MA.
View insider buying and selling activity for Axsome Therapeutics
or view top insider-selling stocks.

Which major investors are buying Axsome Therapeutics stock?

AXSM stock was purchased by a variety of institutional investors in the last quarter, including Private Capital Group LLC. Company insiders that have bought Axsome Therapeutics stock in the last two years include Mark Coleman, Mark E Saad, and Nick Pizzie.
View insider buying and selling activity for Axsome Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Axsome Therapeutics?

Shares of AXSM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Axsome Therapeutics' stock price today?

One share of AXSM stock can currently be purchased for approximately $52.60.

How much money does Axsome Therapeutics make?

Axsome Therapeutics has a market capitalization of $1.97 billion. The company earns $-68,350,000.00 in net income (profit) each year or ($2.01) on an earnings per share basis.

How many employees does Axsome Therapeutics have?

Axsome Therapeutics employs 60 workers across the globe.

What is Axsome Therapeutics' official website?

The official website for Axsome Therapeutics is

Where are Axsome Therapeutics' headquarters?

Axsome Therapeutics is headquartered at 200 BROADWAY 3RD FLOOR, NEW YORK NY, 10038.

How can I contact Axsome Therapeutics?

Axsome Therapeutics' mailing address is 200 BROADWAY 3RD FLOOR, NEW YORK NY, 10038. The company can be reached via phone at 212-332-3241.

This page was last updated on 4/16/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.